Physician profile
Stuart R Farber
NPI 1235224023
$533.07
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2021: $29.76 · 2022: $90.36 · 2023: $41.94 · 2024: $37.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $79.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $79.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $91.46 | 2019-2023 | |
| Avanir Pharmaceuticals, INC. | $78.36 | 2019 | |
| Genentech USA, INC. | $72.56 | 2019 | |
| Biogen, INC. | $70.81 | 2019-2021 | |
| Genzyme Corporation | $35.00 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $26.51 | 2019 | |
| Vertical Pharmaceuticals, LLC | $25.25 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.73 | 2019 | |
| Corium, LLC | $23.89 | 2023 | Adlarity |
| Lilly USA, LLC | $23.64 | 2019-2021 | |
| Mdd US Operations, LLC | $22.04 | 2024 | Gocovri |
| Neurocrine Biosciences, INC. | $15.19 | 2024 | Ingrezza |
| Upsher-Smith Laboratories LLC | $12.09 | 2019 | |
| Supernus Pharmaceuticals, INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Farber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.